acyline Report issue

Small molecule Experimental
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Acyline is a gonadotropin-releasing hormone analogue and gonadotropin-releasing hormone antagonist which was never marketed. It has been shown to suppress gonadotropin and testosterone levels in men. Acyline is a peptide and under normal circumstances is not orally active. For this reason, it has instead been administered by subcutaneous injection.   Wikipedia

Chemistry

  • SMILES: CC(=O)Nc1ccc(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc2ccc(Cl)cc2)NC(=O)[C@@H](Cc2ccc3ccccc3c2)NC(C)=O)C(=O)N[C@H](Cc2ccc(NC(C)=O)cc2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@H](C)C(N)=O)cc1
  • InChIKey: ZWNUQDJANZGVFO-YHSALVGYSA-N
  • Mol. Mass: 1533.24
  • ALogP: Missing data
  • ChEMBL Molecule:
    acyline  
More Chemistry

Pharmacology

Alternative names

acycline | acyline

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Androgens (Phase 1/Phase 2)

Contraception (Phase 1/Phase 2)

Contraceptive Agents, Male (Phase 2)

Deficiency Diseases (Phase 2)

Diabetes Mellitus, Type 2 (Phase 1/Phase 2)

Healthy Volunteers (Phase 2/Phase 3)

Hypogonadism (Phase 1)

Insulin Resistance (Phase 1/Phase 2)

Metabolic Diseases (Phase 1/Phase 2)

Obesity (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue